Patients with high-risk bladder cancer reported similar quality of life when treated with sasanlimab plus BCG versus BCG alone, new study data showed.

Treatment with Zusduri had a median duration of response of 3.5 years and event-free survival of two years in low-grade ...

The first bladder transplant in a living patient is the successful result of years of research and surgical innovation.

Discover a study revealing how chemotherapy-induced tumour pyroptosis reprograms fibroblasts, promoting chemoresistance in ...

This "promising first step" could help to treat bladder, oral, head and neck tumors more effectively, said biomedical ...

A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden’s ...

A recent study reveals low rates of upper tract urothelial carcinoma in non-muscle-invasive bladder cancer, prompting a ...

US patients with metastatic urothelial cancer have seen improvements in survival since ICIs and ADCs have entered the market, data suggest.

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. | The Fierce Biotech Fundraising Tracker records ...